Patlak-Ki derived from ultra-high sensitivity dynamic total body [18F]FDG PET/CT correlates with the response to induction immuno-chemotherapy in locally advanced non-small cell lung cancer patients

Wang, DaQuan; Qiu, Bo; Liu, QianWen; Xia, LiangPing; Liu, SongRan; Zheng, ChaoJie; Liu, Hui; Mo, YiWen; Zhang, Xu; Hu, YingYing; Zheng, ShiYang; Zhou, Yin; Fu, Jia; Chen, NaiBin; Liu, FangJie; Zhou, Rui; Guo, JinYu; Fan, Wei; Liu, Hui

doi:10.1007/s00259-023-06298-x

Cited by 14 publications

(5 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, the effectiveness of ICIs was not investigated. Recently, Wang et al reported that dynamic FDG uptake parameters may be useful in distinguishing responders from non-responders, regardless of PD-L1 expression [ 28 ]. Therefore, there is an urgent need to develop superior biomarkers of response to immunotherapy or immunotherapy-based combination therapy in patients with NSCLC.…”

Section: Discussionmentioning

confidence: 99%

Texture Features of 18F-Fluorodeoxyglucose Positron Emission Tomography for Predicting Programmed Death-Ligand-1 Levels in Non-Small Cell Lung Cancer

Norikane,

Ishimura,

Mitamura

et al. 2024

JCM

View full text Add to dashboard Cite

Background: Identifying programmed death-ligand-1 (PD-L1) expression is crucial for optimizing treatment strategies involving immune checkpoint inhibitors. However, the role of intratumoral metabolic heterogeneity specifically derived from 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) images in predicting PD-L1 expression in patients with newly diagnosed non-small cell lung cancer (NSCLC) remains unexplored. Here, we investigated the association between FDG PET texture features and PD-L1 expression by retrospectively analyzing the data of patients newly diagnosed with NSCLC who underwent FDG PET/CT scans and PD-L1 immunohistochemical staining before treatment. Methods: Patients were categorized based on their tumor proportion scores (TPSs) into negative-, low-, and high-PD-L1 expression groups. We computed the maximum standardized uptake value and 31 texture features for the primary tumor from PET images and compared differences in parameters among the groups. Results: Of the 83 patients, 12, 45, and 26 were assigned to the negative-, low-, and high-PD-L1 expression groups, respectively. Six specific texture features (low gray-level run emphasis, short-run low gray-level emphasis, long-run high gray-level emphasis, low gray-level zone emphasis, high gray-level zone emphasis, and short-zone low gray-level emphasis) helped distinguish among all possible combinations. Conclusions: Our findings revealed that FDG PET texture features are potential imaging biomarkers for predicting PD-L1 expression in patients newly diagnosed with NSCLC.

show abstract

Section: Discussionmentioning

confidence: 99%

Texture Features of 18F-Fluorodeoxyglucose Positron Emission Tomography for Predicting Programmed Death-Ligand-1 Levels in Non-Small Cell Lung Cancer

Norikane,

Ishimura,

Mitamura

et al. 2024

JCM

View full text Add to dashboard Cite

show abstract

“…These quantitative data are crucial for monitoring disease progression, evaluating treatment responses, and guiding treatment decisions. More recently, some technological innovations have further boosted the applications of PET in immuno-oncology, such as the implementation of silicon photomultiplier (SiMP)-based detection, referred to as the "digital PET", and the introduction of long axial field-of-view (LAFOV) PET/CT scanners, capable of covering the entire scan length in a single or a few bed positions, and characterized by exquisite sensitivity [33].…”

Section: Immuno-pet: Basic Principles and Technical Featuresmentioning

confidence: 99%

Immuno-PET for Glioma Imaging: An Update

De Feo,

Granese,

Conte

et al. 2024

Applied Sciences

View full text Add to dashboard Cite

Despite significant advances in glioma diagnosis and treatment, overall outcomes remain suboptimal. Exploring novel therapeutic avenues show promise in advancing the field. Theranostics, an evolving discipline integrating diagnosis and therapy, emerges as a particularly auspicious approach. However, an unmet need exists for glioma-associated biomarkers as theranostic targets. Immuno-positron emission tomography (Immuno-PET), a pioneering method uniting PET diagnostic precision with antibody specificity, holds potential for identifying cancer-associated biomarkers. This review aims to provide an updated overview of immuno-PET applications in gliomas. Notably, [44Sc]-CHX-A″-DTPA-Cetuximab-Fab targeting Epidermal Growth Factor Receptor (EGFR) has displayed promise in glioma xenografts, enabling potential imaging at 4 h post-injection. Similarly, [89Zr]-bevacizumab targeting vascular endothelial growth factor (VEGF) yielded encouraging results in preclinical models and a pioneering clinical trial for pediatric patients with diffuse intrinsic pontine glioma (DIPG). Several cell differentiation markers, including CD146, indicative of tumor aggressiveness, and CD11b, reflecting tumor-associated myeloid cells (TAMCs), proved effective targets for immuno-PET. Additionally, immuno-PET directed at prostate-specific antigen (PSMA) demonstrated efficacy in imaging glioma-associated neovasculature. While holding promise for precise diagnosis and treatment guidance, challenges persist in achieving target specificity and selecting suitable radionuclides. Further studies are imperative to advance the field and bridge a translational gap from bench to bedside.

show abstract

“…The Patlak model is increasingly favored for dynamic 18 F-FDG TB-PET owing to its simplicity [46]. Wang et al [47] found that Patlak-K i derived from dynamic 18 F-FDG TB-PET correlates with the response of patients with locally advanced non-small cell lung cancer to induction immuno-chemotherapy.…”

Section: Parametric Imagingmentioning

confidence: 99%

“…Owing to its high sensitivity, resolution, and complete coverage of all organs, TB-PET not only produces superior images [2][3][4] with reduced radiation doses [7,14,16,17,20,54] and scan times [5,6,8,9] but also enables the transformation of PET from traditional single-parameter imaging to multi-parameter imaging [39,42,[47][48][49][50]52]. Previously impossible, TB-PET enables the determination of radiotracer kinetics and distribution across multiple organs, which facilitates the elucidation of interrelationships among physiological/pathological factors influencing the distribution of specific radiotracers between organs [1,11,26,41,55].…”

Section: Perspectivementioning

confidence: 99%

Current progress and future perspectives in total‐body positron emission tomography/computed tomography. Part II: Clinical applications

Chen,

Sun,

Huang

et al. 2024

iRADIOLOGY

View full text Add to dashboard Cite

Total‐body positron emission tomography (TB‐PET) has significantly advanced from initial conception to global commercial availability. The high sensitivity of TB‐PET has led to superior lesion detection, thereby expanding the range of clinical applications. TB‐PET technology offers several advantages: (a) It enables the detection of small lesions, facilitating precise cancer staging and targeted cancer formulation. (b) The technology shortens the acquisition time while maintaining the quality of diagnostic images. (c) TB‐PET allows for a reduction in the amount of administered radiotracer, which minimizes image noise, reduces the effective radiation dose to patients, and enhances staff safety. (d) The scanner supports the development of new tracers and the dynamic imaging of these tracers throughout the entire body. (e) TB‐PET accommodates delayed scanning, which has been shown to improve the detection of small and previously undetected malignant lesions by enhancing the clearance in areas of significant background activity. (f) Owing to its high‐quality images, TB‐PET is suitable for parametric imaging, which offers several advantages over conventional standardized uptake value imaging. However, TB‐PET still faces several challenges. There is a lack of consensus on the optimal dose and scan duration for clinical diagnosis using TB‐PET. Additionally, unified standards for parametric imaging via TB‐PET are yet to be established, and the full clinical significance of this technology remains under‐explored. The accompanying review (Part 1) covers TB‐PET data manipulation and analysis.

show abstract

Patlak-Ki derived from ultra-high sensitivity dynamic total body [18F]FDG PET/CT correlates with the response to induction immuno-chemotherapy in locally advanced non-small cell lung cancer patients

Cited by 14 publications

References 47 publications

Texture Features of 18F-Fluorodeoxyglucose Positron Emission Tomography for Predicting Programmed Death-Ligand-1 Levels in Non-Small Cell Lung Cancer

Texture Features of 18F-Fluorodeoxyglucose Positron Emission Tomography for Predicting Programmed Death-Ligand-1 Levels in Non-Small Cell Lung Cancer

Immuno-PET for Glioma Imaging: An Update

Current progress and future perspectives in total‐body positron emission tomography/computed tomography. Part II: Clinical applications

Contact Info

Product

Resources

About